Jane Street reports 1.7% stake in Co-Diagnostics
Co-Diagnostics, Inc. has an updated ownership disclosure showing that entities affiliated with Jane Street hold a relatively small position in its common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Co-Diagnostics, Inc. has an updated ownership disclosure showing that entities affiliated with Jane Street hold a relatively small position in its common stock. Jane Street Group, LLC, together with subsidiaries Jane Street Capital, LLC and Jane Street Global Trading, LLC, report beneficial ownership of 89,240 shares of Co-Diagnostics common stock, representing 1.7% of the class. All reported shares are held with shared voting and dispositive power and no sole voting or dispositive power. The filing also confirms that the reporting group now owns 5 percent or less of the outstanding common stock.
Key Figures
Key Terms
beneficially owned financial
parent holding company financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Co-Diagnostics (CODX) does Jane Street report in this Schedule 13G/A?
Which Jane Street entities are reporting ownership of Co-Diagnostics (CODX)?
Does Jane Street own more than 5% of Co-Diagnostics (CODX) common stock?
What roles do Jane Street Capital, LLC and Jane Street Global Trading, LLC play in the Co-Diagnostics (CODX) position?
AI-generated analysis. How Rhea-AI works. Not financial advice.